Posted on Jan 27, 2020

Healthcare Medical Pharmaceutical Directory

HORIZON THERAPEUTICS INTRODUCES TEPEZZA (teprotumumab-trbw) FOR THYROID EYE DISEASE (TED) - John G. Baresky

Horizon Therapeutics (NASDAQ: HZNP) has received FDA approval for its thyroid eye disease Tepezza (teprotumumab-trbw). Thyroid eye disease (TED) is a healthcare condition centered on inflammation of the eyes, eye muscles, eyelids, tear glands and fatty tissues behind the eye.

TED is also known as Graves’ Orbitopathy or Ophthalmopathy and is an autoimmune condition. TED’s symptoms include outward bulging of the eye which may cause a series of problems such as double vision, eye pain, light sensitivity or issues with closing the eye.

Tepezza (teprotumumab-trbw) is a biologic or biotherapy agent as it is a fully human monoclonal antibody (mAb) and a targeted inhibitor of the insulin-like growth factor 1 receptor (IGF-1R).

As part of the FDA's approval of Tepezza, Horizon will continue monitoring Tepezza’s therapeutic activity in a post marketing study to assess its safety profile in a larger patient population.

Read the bulletin for complete details now...
Contact Us
Message sent. We'll get back to you soon.